The Innovation at a Glance
Patent US11571484B2, titled "Compositions that target tumor-associated macrophages and methods of use therefor," introduces a set of peptides and compositions designed for multifaceted use in diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating conditions including cancer, inflammatory disorders, and autoimmune diseases. The patent exemplifies a technically sophisticated approach by focusing on tumor-associated macrophages, which play critical roles in the tumor microenvironment and inflammation pathways. By combining peptide-based compositions with diagnostic and therapeutic functionalities, the invention addresses intricate bioengineering challenges that are central to advancing precision medicine in oncology and immune-related diseases.
The Inventor & Company Behind It
The assignee, Sanford Burnham Prebys Medical Discovery Institute, is recognized in the biomedical research community for pioneering innovations in disease biology and therapeutic development. This patent reflects the institution’s strategic emphasis on translational research that bridges molecular discoveries with clinical applications. The technology underscores their commitment to developing targeted molecular tools that can both detect and intervene in complex pathological processes, thereby driving forward potential integrated solutions in healthtech.
Market Opportunity
The patent operates at the intersection of diagnostics and therapeutics within oncology and immunology, two sectors experiencing rapid innovation and intense competition. Targeting tumor-associated macrophages presents a compelling therapeutic angle due to their influence on tumor progression and immune response modulation. Although the potential clinical impact is significant, commercial realization faces typical challenges including regulatory pathways, product maturation timelines, and competitive pressures from established and emerging therapies. The dual utility of this technology in both imaging and treatment could enable differentiated value propositions in diagnostic imaging markets and targeted therapeutics.
Growth Indicators
With a citation count of 345, US11571484B2 demonstrates strong recognition and influence within the scientific and patent communities. The patent's Healthtech Innovation Score (HIS) of 75.8 reflects a robust technological foundation combined with moderate productization readiness in the healthtech space. Consistent licensing interest suggests growing attention from industry players looking to augment their portfolios with novel immunomodulatory technologies, even as further development is necessary to achieve full commercial potential.
Why IP Investors Are Watching
Investors in intellectual property are monitoring this patent due to its integrative approach blending diagnostics and therapeutics aimed at a strategic biological target. The patent’s broad applicability across cancer and inflammatory diseases positions it well within prevailing healthcare trends emphasizing personalized and targeted interventions. While risks associated with clinical development and market entry remain, Sanford Burnham Prebys Medical Discovery Institute’s strong research pedigree and the patent’s demonstrated technological impact provide reason for cautious optimism. The patent’s ability to attract sustained citations and licensing interest highlights its potential role within a competitive innovation landscape.
Get the Full Analysis
For investors seeking a detailed understanding of US11571484B2’s positioning, technological merits, and strategic value, a comprehensive report is available through IPI Terminal. This analysis includes assessment of patent family scope, landscape comparisons, competitor benchmarking, and pathway to commercialization insights to inform high-level IP investment decisions in the evolving healthtech domain.